Amgen, US FDA and colorectal
We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...
Piper Sandler reiterated its Overweight rating on Amgen (NASDAQ:AMGN) shares, maintaining a price target of $310.00. The company, which boasts a "GOOD" overall financial health score according to ...
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
GlobalData on MSN5d
JP Morgan 2025: reduced dosing and expanded manufacturing paving way for Amgen’s obesity entranceAmgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and ...
Amgen has announced a $1 billion expansion in Holly Springs and has signed a dozen students from Wake Technical Community ...
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...
Amgen (AMGN) announced that the U.S. FDA has approved Lumakras in combination with Vectibix for the treatment of adult patients with KRAS ...
Amgen is on pace to return to its pre-Horizon capital structure by the end of 2025. Learn why I upgrade AMGN stock from hold ...
Amgen Inc. closed $79.75 short of its 52-week high ($346.85), which the company achieved on July 25th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback